Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion acquired 2,000,000 shares (KRW 10 billion) of its newly established Contract Development and Manufacturing Organization (CDMO) entity, ‘Celltrion BioSolutions,’ via cash contribution, securing a 100% equity stake as a wholly-owned subsidiary.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Decision on Acquisition of Shares and Investment Certificates in Another Corporation (Voluntary Disclosure)
- Board Resolution Date (CEO Approval Date): December 17, 2024
- Scheduled Acquisition Date: December 17, 2024
- Target Company Overview
- Company Name: Celltrion BioSolutions
- Representative: Lee Hyuk-jae
- Stated Capital: KRW 10,000,000,000 (KRW 10B)
- Relationship: Affiliated Company (Wholly-owned Subsidiary)
- Primary Business: Development, manufacturing, commercialization, distribution, and sale of pharmaceuticals including biopharmaceuticals
- Acquisition Details & Purpose
- Number of Shares Acquired: 2,000,000 shares
- Total Acquisition Amount: KRW 10,000,000,000 (KRW 10B)
- Ratio to Total Equity: 0.06% (Based on consolidated equity of KRW 17.125T at end-2023)
- Shares Held & Ownership After Acquisition: 2,000,000 shares (100%)
- Method of Acquisition: Cash Contribution
- Purpose of Acquisition: Establishment of CDMO entity (Business expansion through subsidiary setup)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring CDMO Business Launch and Periodic Filings Update
This disclosure serves as official notification that Celltrion acquired a 100% equity stake to establish ‘Celltrion BioSolutions’ as a wholly-owned subsidiary dedicated to CDMO operations. Tracking the formal registration of the subsidiary, execution of initial infrastructure investments, and proper inclusion under consolidated subsidiary lists in future periodic reports is important for assessing execution progress. Relevant updates can be confirmed through subsequent periodic reports or official IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
